Currently, 90 percent of drugs fail in one of the four phases of human trials. AI-based discovery approaches could screen the properties of millions of molecules and protein properties to find the best matches—the ones that are most likely to have a positive impact on understanding complex disease states.
Laboratory Equipment is powered by Labcompare. You are receiving this email because you are subscribed to our database. Need to change your settings? Email Settings or Unsubscribe here
